When Wegovy starts working — and how to tell it is

The earliest signs: what weeks one to four actually feel like

The decision most people face first is this: should I trust what I feel, or wait for the scales? In weeks one to four, the scales will likely disappoint you. That is normal. Wegovy is titrated slowly, the 0.25 mg starting dose is designed to let your body adjust, and the clinical effect on fat loss is modest at this stage. What you are more likely to notice is a quieter appetite. Food that used to feel urgent feels manageable. Portion sizes shrink without a fight.

This is the GLP-1 mechanism at work. Semaglutide acts on receptors in the gut and brain involved in satiety and reward signalling, and it slows how quickly your stomach empties. The NHS medicines page for semaglutide describes this dual action clearly. If you are wondering about how long Wegovy takes to start working, the appetite change is real and clinically meaningful, it is just not yet visible on the scales at week two. Side effects are also most common in this window: nausea, loose stools, and fatigue are frequently reported after starting or after a dose increase. They generally ease within days to two weeks.

One practical habit worth building early: step on the scales once a week, at the same time of day, ideally in the morning before eating. That single consistent measurement strips out the noise of hydration and clothing and gives you a genuine trend line, rather than a daily anxiety spiral. Take a note on your phone. That is it, under a minute, and it tells you everything you need over the following months.

Weeks four to twelve: when weight loss starts to show up

By the four-week mark most people have moved to 0.5 mg, and this is where the scale tends to start shifting. The decision here is whether to interpret early, modest loss as failure. It is not. Research published in the STEP 1 trial in the New England Journal of Medicine tracked 68 weeks of treatment; the trajectory was a steady downward slope, not a dramatic early drop. Expecting dramatic results at week six sets people up to stop a treatment that was working fine.

Dose increases continue through this phase. Each step up (from 0.5 mg to 1.0 mg, then to 1.7 mg) brings a renewed appetite-suppressing effect, and sometimes a brief return of nausea. The titration exists for a reason: arriving at maintenance dose on a body that has already adjusted makes the full effect more sustainable. You can find a full overview of the treatment pathway on our Wegovy treatment page.

Weight loss of one to two pounds a week is a reasonable expectation in this phase, though there will be weeks with nothing and weeks with more. Lifestyle (protein intake, sleep, physical activity) interacts with the medicine's effect. The prescriber who reviewed your case will be the right person to interpret your specific progress; the numbers from a trial average do not describe any individual.

Months three to six and the maintenance dose: the decision about whether it is working

Reaching 2.4 mg is the point at which the question "is Wegovy working for me?" has a real answer. NICE guidance on semaglutide (published as TA875) sets a clear threshold: less than 5% body-weight reduction after six months at maintenance dose is the point at which continuing treatment should be formally reviewed. That is a clinically meaningful benchmark, not a pass-fail test, it is the trigger for an honest conversation with your prescriber about whether adjusting approach, considering a higher dose, or exploring an alternative makes sense.

For most people who reach 2.4 mg and stick with the lifestyle changes, the six-month check is reassuring rather than alarming. The STEP 1 data showed an average reduction of around 15% over 68 weeks, a figure built almost entirely in months three through sixteen, not in the first four weeks. You can read more about what shapes the overall outcome on our semaglutide information page.

It is also worth knowing that the MHRA has now approved a 7.2 mg maintenance dose for eligible adults with a BMI of 30 or above. If you are approaching the ceiling of 2.4 mg without the response you were hoping for, that option exists, but it requires a prescriber's clinical assessment, not a self-directed dose increase. Details of the higher-dose pen approval are covered on our more detailed timeline page.

When Wegovy is working and you cannot tell yet: keeping perspective

The gap between biological effect and visible result is genuinely frustrating. Many patients ask when Wegovy starts working and are surprised to learn that the medicine begins acting on appetite and metabolic signalling from the first injection. The body-composition changes that follow take time to accumulate into something the scales reflect. That lag is not a sign the medicine has failed; it is how gradual fat loss works.

Some people also notice non-scale markers first: clothes fitting differently, energy levels steadying, blood sugar readings (if monitored) improving before weight has shifted significantly. These are legitimate signals worth tracking alongside the scales. Understanding what Wegovy actually does when it starts working can help you recognise these early changes for what they are, rather than dismissing them. If you are unsure whether your trajectory is on track, or if side effects are making the titration difficult, that is precisely what aftercare support is for. Our team at nume provides prescriber-led aftercare seven days a week, not just at prescription renewal. The FAQs page covers common concerns, and you can reach us directly through our contact page.

Wegovy is a prescription-only medicine. If you have not yet had a clinical assessment and want to understand whether it might be appropriate for your situation, our prescribers can review your case. Speak to our prescribers through a free consultation, same-day clinical review, no waiting list.